Scancell pivots back to a subgroup
The company claims a 69% response rate with iSCIB1+, but only in a “target population”.
FDA rejects Replimune’s oncolytic virus
There are questions about vuso-vec’s supporting and confirmatory trials.
Erasca enters its pan-RAS era
The company deprioritises its lead project, naporafenib, shifting to two Joyo-originated assets.
Mural hits a wall
The company scraps nemvaleukin after the latest failure, of Artistry-6.
Mural fails to paint a convincing picture for nemvaleukin
The Artistry-7 Keytruda combo trial fails, spurring discontinuation in ovarian cancer.
What future for Lag3 blockade?
Opdualag chalks up another failure, this time in the extension of an approved use.
Regeneron’s lung cancer Lag3 lag
Fianlimab NSCLC data are delayed, while odronextamab gets a DLBCL blow.
Scancell’s dilemma delayed
The group touts a 72% ORR with SCIB1, but full Scope data have been pushed back into 2025.
